IRCT20210828052313N1
Recruiting
Phase 3
The effect of different doses of empagliflozin on quality of life, heart function, atherosclerosis, vascular inflammation, blood pressure and lipid profile in non-diabetic patients with heart failure
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Heart Failure.
- Sponsor
- Shiraz University of Medical Sciences
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Recruiting
Phase 2
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesCardiomyopathyK75.81IRCT20190122042450N5Iran University of Medical Sciences70
Not yet recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Not yet recruiting
Phase 3
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128